Notizie Ypsomed Italia

Berthoud - Ypsomed lance l'administration de bolus depuis un smartphone vers la pompe à insuline mylife YpsoPump1 via l'application mylife App. Cette nouvelle fonctionnalité permet aux utilisateurs de mylife YpsoPump d'administrer un bolus d'insuline de manière pratique et discrète via un smartphone, sans avoir à manipuler directement la pompe. Suite au lancement au début de l'été, dans certains pays Européens, de l'administration automatisée d'insuline (AAI) via l'application mylife CamAPS FX, Ypsomed propose désormais une option supplémentaire d'administration discrète de bolus à distance aux personnes diabétiques, leur permettant de choisir une solution thérapeutique répondant à leurs besoins.

Press Releases Ypsomed Group

Burgdorf – Ypsomed, Abbott and CamDiab will work to accelerate the development of an automated insulin delivery system for people living with diabetes. The system is being designed to include Abbott’s FreeStyle Libre 3 sensor, CamDiab’s CamAPS FX algorithm, and Ypsomed’s mylife YpsoPump. The partnership demonstrates the companies’ collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes.

Ypsomed continues to invest in growth

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) increased its consolidated sales by CHF 9.4 million to CHF 403.7 million in the financial year 2020/21 (prior year: CHF 394.3 million). The two business segments developed differently during the Corona pandemic: while the business with pens and autoinjectors was encouraging, the sales of insulin pumps remained at a low level. Ypsomed has set an important course in the financial year 2020/21 to improve the sales opportunities for YpsoPump. The increased importance of self-treatment of chronic diseases has reinforced the company’s growth strategy. Ypsomed has therefore advanced all strategic initiatives and further improved its own competitive position. The company invested a total of CHF 142.7 million for this purpose while at the same time creating 110 new jobs. To expand financial flexibility for the future, the Board of Directors will propose an authorised increase in capital at the Annual General Meeting.

World's first zero carbon emission autoinjector from Ypsomed

Press Releases Ypsomed Group

Burgdorf – Ypsomed has developed the world’s first zero carbon emission prefilled autoinjector. The YpsoMate Zero is based on the proven YpsoMate autoinjector platform that offers convenient handling and patient safety. The new YpsoMate Zero uses alternative biopolymers and a novel packaging design that follows the principles of circular product design.

Ypsomed’s Annual General Meeting approves all proposals and elects Gilbert Achermann as a new member of the Board of Directors

Press Releases Ypsomed Group

Burgdorf – Yesterday, the Annual General Meeting of the Ypsomed Group has approved all proposals and has elected Gilbert Achermann as a new member of the Board of Directors and of the Compensation Committee to succeed Anton Kräuliger. Gilbert Achermann is Chairman of the Board of Directors of the Straumann Group as well as member of the Board of Directors of Vifor Pharma Ltd and Julius Baer Group Ltd.